S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
NFLX   326.00 (-3.58%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:ZSAN - Zosano Pharma Stock Price, Forecast & News

$1.42
-0.03 (-2.07 %)
(As of 01/22/2020 04:00 PM ET)
Today's Range
$1.40
Now: $1.42
$1.47
50-Day Range
$1.37
MA: $1.50
$1.71
52-Week Range
$1.27
Now: $1.42
$6.65
Volume336,820 shs
Average Volume313,393 shs
Market Capitalization$25.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.56 per share

Profitability

Net Income$-35,360,000.00

Miscellaneous

Employees53
Market Cap$25.89 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

The audience GASPED when he revealed how you could collect 100% on your savings every year... for life.

Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Shares of Zosano Pharma reverse split before market open on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Corp (NASDAQ:ZSAN) issued its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.55) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.03. View Zosano Pharma's Earnings History.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Zosano Pharma.

What price target have analysts set for ZSAN?

3 analysts have issued 12 month price targets for Zosano Pharma's stock. Their forecasts range from $6.00 to $16.00. On average, they expect Zosano Pharma's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 604.2% from the stock's current price. View Analyst Price Targets for Zosano Pharma.

What is the consensus analysts' recommendation for Zosano Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.

Has Zosano Pharma been receiving favorable news coverage?

News coverage about ZSAN stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Zosano Pharma earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Zosano Pharma.

Who are some of Zosano Pharma's key competitors?

What other stocks do shareholders of Zosano Pharma own?

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the folowing people:
  • Mr. John P. Walker, Chairman, CEO & Pres (Age 70)
  • Ms. Hayley Lewis, Sr. VP of Operations (Age 43)
  • Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 64)
  • Mr. Greg Kitchener, Chief Financial Officer (Age 48)
  • Jeffrey L. Quillen, Sec.

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.55%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc and John Peter Walker. View Institutional Ownership Trends for Zosano Pharma.

Which major investors are selling Zosano Pharma stock?

ZSAN stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Zosano Pharma.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $1.42.

How big of a company is Zosano Pharma?

Zosano Pharma has a market capitalization of $25.89 million. The biotechnology company earns $-35,360,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.View Additional Information About Zosano Pharma.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is http://www.zosanopharma.com/.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]


MarketBeat Community Rating for Zosano Pharma (NASDAQ ZSAN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe ZSAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel